Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised,…

By Eugene D Kwon, C. Drake, H. Scher, K. Fizazi, A. Bossi, A. van den Eertwegh, M. Krainer, N. Houédé, Ricardo Santos, H. Mahammedi and 16 more. The Lancet Oncology, 2014

1,394 citations recorded by the source corpus.

Summary Background Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. Our aim was to assess the use of ipilimumab after radiotherapy in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel chemotherapy. Methods We did a multicentre, randomised, double-blind, phase 3 trial in which men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment were randomly assigned in a 1:1 ratio to receive bone-directed radiotherapy (8 Gy in one fraction) followed by either ipilimumab 10 mg/kg or placebo every 3 weeks for up to four doses. Non-progressing patients could continue to receive ipilimumab at 10 mg/kg or placebo as maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death. Patients were randomly assigned to either treatment group via a minimisation algorithm, and stratified by Eastern Cooperative Oncology Group performance status, alkaline phosphatase concentration, haemoglobin concentration, and investigator site. Patients and investigators were masked to treatment allocation. The primary endpoint was overall survival, assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00861614. Findings From May 26, 2009, to Feb 15, 2012, 799 patients were randomly assigned (399 to ipilimumab and 400 to placebo), all of whom were included in the intention-to-treat analysis. Median overall survival was 11·2 months (95% CI 9·5–12·7) with ipilimumab and 10·0 months (8·3–11·0) with placebo (hazard ratio [HR] 0·85, 0·72–1·00; p=0·053). However, the assessment of the proportional hazards assumption showed that it was violated (p=0·0031). A piecewise hazard model showed that the HR changed over time: the HR for 0–5 months was 1·46 (95% CI 1·10–1·95), for 5–12 months was 0·65 (0·50–0·85), and beyond 12 months was 0·60 (0·43–0·86). The most common grade 3–4 adverse events were immune-related, occurring in 101 (26%) patients in the ipilimumab group and 11 (3%) of patients in the placebo group. The most frequent grade 3–4 adverse events included diarrhoea (64 [16%] of 393 patients in the ipilimumab group vs seven [2%] of 396 in the placebo group), fatigue (40 [11%] vs 35 [9%]), anaemia (40 [10%] vs 43 [11%]), and colitis (18 [5%] vs 0). Four (1%) deaths occurred because of toxic effects of the study drug, all in the ipilimumab group. Interpretation Although there was no significant difference between the ipilimumab group and the placebo group in terms of overall survival in the primary analysis, there were signs of activity with the drug that warrant further investigation. Funding Bristol-Myers Squibb.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/f3c039da4b6754dae23673fb178a6c58fd4e492a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pulmonary and Respiratory Medicine

Eleftherios P. Diamandis

In Radiology, Nuclear Medicine and Imaging

M. Lacouture

Citations in the corpus

Immune checkpoint blockade: a common denominator approach to cancer therapy (2015, methodology): “053), failing to meet the trial’s primary endpoint (Kwon et al., 2014).”
Management of toxicities of immune checkpoint inhibitors. (2016, background): “These side effects are generally manageable but can be fatal in some cases [2–5].”
New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management (2017, background): “Furthermore, cases of intestinal perforation have been described and urgent assessment and management are recommended in suspicious cases [21, 22].”
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. (2017, background): “Treatment with single-agent ipilimumab 10 mg/kg after bone-directed radiotherapy (8 Gy in one fraction) in a randomized phase III trial (CA184-043) in patients with mCRPC, at least one bone metastasis, and disease progression after docetaxel therapy demonstrated antitumor activity (improvement in pr”
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021, background): “Frequency of intestinal perforation has been described at approximately 1% of patients with colitis.(64,67,68)”
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (2018, background): “Frequency of intestinal perforation has been described at approximately 1%.(16,20) The most common clinical presentations of immune-related GI toxicities vary from very frequent and/or loose stools to colitis symptoms (eg, mucous in the stools, abdominal pain, fever, rectal bleeding).”
Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “2 months for radiotherapy followed by ipilimumab [149]”
Immune Checkpoint Targeting in Cancer Therapy: Towards Combination Strategies with Curative Potential (2015, background): “However, subset analyses indicate that patients who have favorable clinical characteristics such as lack of liver metastases do benefit from ipilimumab therapy (Kwon et al., 2014).”
Immune Checkpoint Blockade in Cancer Therapy. (2015, result): “Unfortunately, a phase III study in patients with castrateresistant prostate cancer who experienced progression on docetaxel chemotherapy demonstrated that after radiotherapy, ipilimumab did not improve overall survival compared with placebo.(22) Although this study is felt to have been a negative s”
Immune-related adverse events with immune checkpoint blockade: a comprehensive review. (2016, neutral): “[2,51,67,68], anti-PD-1 [3,11,19,33,59,69,70] or anti-PD-L1”
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017, background): “, severe colitis, pneumonitis, encephalitis, toxic epidermal necrolysis, myocarditis, and autoimmune type I diabetes mellitus [T1DM] presenting as diabetic ketoacidosis), are reported in the literature, and treatment-related deaths have been reported in up to 2% of patients in clinical trials [14, 2”
Genetics and biology of prostate cancer (2018, background): “However, unlike the success of monotherapy or combination therapy in other cancer types, effective strategies have yet to emerge in the treatment of prostate cancer despite the development of checkpoint blockade immunotherapy, as discussed above (Kwon et al. 2014; Beer et al. 2017).”